Ceribell to Report Third Quarter 2025 Financial Results on November 4, 2025

Rhea-AI Summary

Ceribell (Nasdaq: CBLL) will release its third quarter 2025 financial results after the close of trading on Tuesday, November 4, 2025.

Company management will host a conference call to discuss results at 1:30 p.m. PT / 4:30 p.m. ET on November 4, 2025. Domestic callers can dial (800) 715-9871, international callers (646) 307-1963, and use access code 9394689. A live and archived webcast will be available in the Investor Relations section of Ceribell's website at https://investors.ceribell.com/.

SUNNYVALE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the third quarter of 2025 after the close of trading on Tuesday, November 4, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November 4, 2025.

Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 9394689. A live and archived webcast of the event will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.

About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.

Investor Contact
Brian Johnston or Laine Morgan
Gilmartin Group
Investors@ceribell.com

Media Contact
Brian Price
Press@ceribell.com

FAQ

When will Ceribell (CBLL) report Q3 2025 financial results?

Ceribell will release Q3 2025 results after the close of trading on November 4, 2025.

What time is the Ceribell (CBLL) conference call on November 4, 2025?

The conference call begins at 1:30 p.m. PT / 4:30 p.m. ET on November 4, 2025.

How can investors join the Ceribell (CBLL) Nov. 4, 2025 earnings call by phone?

Domestic dial (800) 715-9871 or international dial (646) 307-1963 and enter access code 9394689.

Will there be a webcast for Ceribell's (CBLL) Q3 2025 results and where is it available?

Yes. A live and archived webcast will be available in the Investor Relations section at https://investors.ceribell.com/.

Is the Ceribell (CBLL) Q3 2025 webcast archived for later listening?

Yes. The announcement specifies a live and archived webcast will be available on the investor site.

What access code is required to join the Ceribell (CBLL) earnings call on Nov 4, 2025?

Use access code 9394689 when dialing the provided conference numbers.